Apolipoprotein Mimetic Peptides: An Emerging Therapy against Diabetic Inflammation and Dyslipidemia
Obesity has achieved epidemic status in the United States, resulting in an increase in type 2 diabetes mellitus, dyslipidemia, and cardiovascular disease. Numerous studies have shown that inflammation plays a key role in the development of insulin resistance and diabetic complications. HDL cholester...
Main Authors: | Paul Wolkowicz, C. Roger White, G. M. Anantharamaiah |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/11/5/627 |
Similar Items
-
Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review
by: C. Roger White, et al.
Published: (2014-10-01) -
Novel fatty acyl apoE mimetic peptides have increased potency to reduce plasma cholesterol in mice and macaques[S]
by: G.M. Anantharamaiah, et al.
Published: (2018-11-01) -
How realistic are the LDL-C targets in new dyslipidemia guidelines - is it possible to reach the targets?
by: Barış Güngör
Published: (2020-03-01) -
Risk Analysis and Assessment of Lipid Abnormalities as the Earliest Complication in Newly Diagnosed Diabetic and Non-Diabetic Individuals of a Local Population
by: Zunaira Ali Baig, et al.
Published: (2022-11-01) -
The murine macrophage apoB-48 receptor gene (Apob-48r)homology to the human receptor1
by: Matthew L. Brown, et al.
Published: (2002-08-01)